Clinical outcomes of patients with diabetes mellitus and acute ST-elevation myocardial infarction following fibrinolytic therapy: a nationwide inpatient sample (NIS) database analysis. (3rd April 2021)

• Record Type: Journal Article
• Authors: Ullah, Waqas; Saleem, Sameer; Zahid, Salman; Sattar, Yasar; Mukhtar, Maryam; Younas, Sundas; Pasha, Ahmed K.; Inayat, Asad; Fischman, David L.; Alraies, M. Chadi
• Is Part Of: Expert review of cardiovascular therapy. Volume 19:Number 4(2021)
• Page Start: 357
• Page End: 362
• Publication Date: 2021-04-03
• Subjects: Diabetes -- DM -- STEMI -- ACS -- MI -- fibrinolytics; Cardiovascular agents -- Research -- Periodicals; 616.12061
• DOI: 10.1080/14779072.2021.1888716
• Languages: English
• ISSNs: 1477-9072

Abstract

ABSTRACT: The impact of diabetes mellitus (DM) on clinical outcomes of acute ST-segment elevation myocardial infarction (STEMI) following fibrinolytic therapy remains uncertain. We queried the National Inpatient Sample (NIS) for STEMI patients who received fibrinolytic therapy. Categorical and continuous variables were compared using the unadjusted odds ratio (uOR) and t-test analysis, respectively. A binary logistic regression model was used to control the outcomes for patient demographics, procedural characteristics, and baseline comorbidities. A total of 111, 155 (no-DM 84, 146, DM 27, 009) were included. The unadjusted odds of in-hospital mortality (8.4% vs. 6.8%, uOR 1.25, 95% CI 1.19–1.31, P = <0.0001) and cardiogenic shock (7.7% vs. 6.2%, uOR 1.26, 95% CI 1.20–1.33, P = <0.0001) were significantly higher in patients with DM compared to those with no DM, respectively. The odds for major bleeding and cardiopulmonary arrest were significantly lower for in diabetes. The adjusted pooled estimates mirrored the unadjusted findings. Diabetic patients receiving fibrinolytic therapy for STEMI might have higher odds of all-cause mortality and cardiogenic shock compared to non-diabetic patients.